|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.30 NOK | +0.90% |
|
+1.36% | +61.59% |
| 07-13 | Zelluna Doses First Patient in Phase 1 Cancer Therapy Candidate Trial | MT |
| 07-13 | Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial | CI |
| Market Cap | 641M 66.6M 58.38M 54.09M 49.79M 93.88M 6.41B 95.02M 646M 253M 3.14B 250M 245M 10.85B | P/E 2024 * |
-
| P/E 2025 | -1.95x |
|---|---|---|---|---|---|
| Enterprise Value | 564M 58.54M 51.31M 47.55M 43.76M 82.52M 5.64B 83.52M 567M 222M 2.76B 220M 215M 9.54B | EV / Sales 2024 * |
-
| EV / Sales 2025 | - |
| Free-Float |
66.78% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +0.90% | ||
| 1 week | +1.36% | ||
| Current month | +18.62% | ||
| 1 month | +17.37% | ||
| 3 months | -7.08% | ||
| 6 months | +52.22% | ||
| Current year | +61.59% |
| 1 week | 20.4 |  | 22.8 |
| 1 month | 17.95 | | 23 |
| Current year | 12.9 | | 35.8 |
| 1 year | 8.2 | | 35.8 |
| 3 years | 8.2 | | 35.8 |
| 5 years | 8.2 | | 35.8 |
| 10 years | 8.2 | | 35.8 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/8/23 | Langøya Invest AS
| Buy | Company | 7,000 | 0.0204% | |
| 6/8/23 | Radiumhospitalets Forskningsstiftelse
| Buy | Company | 7,100 | 0.0206% | |
| 11/29/22 | Buy | 1,500 | 0.0044% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.90% | +1.36% | +58.16% | - | 66.6M | |
| -4.86% | -7.02% | -2.59% | +11.35% | 48.5B | |
| +1.11% | +0.10% | +382.41% | +611.72% | 38.97B | |
| +1.25% | +3.83% | +9.33% | +65.52% | 35.43B | |
| -0.88% | -3.59% | +6.40% | -12.61% | 33.65B | |
| -0.87% | -1.56% | -1.43% | +29.16% | 26.58B | |
| -0.60% | -5.61% | - | - | 16.82B | |
| +0.79% | +0.70% | +11.56% | +115.83% | 15.18B | |
| +1.46% | +1.99% | +11.55% | +15.49% | 13.89B | |
| -0.02% | -3.83% | +2.47% | -31.79% | 12.76B | |
| Average | -0.16% | -0.95% | +53.10% | +100.58% | 24.19B | |
| Weighted average by Cap. | -0.73% | -1.28% | +69.57% | +127.25% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 53K 5.51K 4.83K 4.47K 4.12K 7.76K 530K 7.85K 53.36K 20.88K 260K 20.67K 20.22K 897K | - |
| Net income | -105M -10.92M -9.57M -8.87M -8.17M -15.4M -1.05B -15.58M -106M -41.43M -516M -41M -40.12M -1.78B | -141M -14.62M -12.81M -11.87M -10.93M -20.6M -1.41B -20.85M -142M -55.44M -690M -54.86M -53.68M -2.38B |
| Net Debt | -27.56M -2.86M -2.51M -2.33M -2.14M -4.04M -276M -4.08M -27.75M -10.86M -135M -10.75M -10.52M -467M | -77.6M -8.06M -7.07M -6.55M -6.03M -11.36M -776M -11.5M -78.13M -30.58M -380M -30.26M -29.61M -1.31B |
Employees
15
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-21 | NOK 21.80 | -2.24% | 12,002 |
| 26-07-20 | NOK 22.30 | +0.90% | 18,640 |
| 26-07-17 | NOK 22.10 | +0.91% | 9,798 |
| 26-07-16 | NOK 21.90 | -3.95% | 11,040 |
| 26-07-15 | NOK 22.80 | +3.64% | 27,410 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ZLNA Stock
Select your edition
All financial news and data tailored to specific country editions
